Olfactory threshold predicts treatment response in relapsing multiple sclerosis

被引:3
|
作者
Bsteh, Gabriel [1 ]
Hegen, Harald [2 ]
Berek, Klaus [2 ]
Altmann, Patrick [1 ]
Auer, Michael [2 ]
Di Pauli, Franziska [2 ]
Haider, Lukas [3 ]
Leutmezer, Fritz [1 ]
Rommer, Paulus [1 ]
Walchhofer, Lisa-Maria [4 ]
Wurth, Sebastian [5 ]
Zinganell, Anne [2 ]
Deisenhammer, Florian [2 ]
Berger, Thomas [1 ]
机构
[1] Med Univ Vienna, Dept Neurol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
[2] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria
[3] Med Univ Vienna, Dept Neuroradiol, Vienna, Austria
[4] Med Univ Innsbruck, Dept Neuroradiol, Innsbruck, Austria
[5] Med Univ Graz, Dept Neurol, Graz, Austria
关键词
Multiple sclerosis; olfactory threshold; disease-modifying treatment; relapse; MRI; treatment response; INTERFERON-BETA; DYSFUNCTION; SMELL; MRI;
D O I
10.1177/13524585221079744
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Olfactory threshold (OT) is associated with short-term inflammatory activity in relapsing multiple sclerosis (RMS). Objective: We aimed to investigate OT for prediction of treatment response in RMS. Methods: In this 5-year prospective study on 123 RMS patients, OT was measured at disease-modifying treatment (DMT) initiation (M0), after 3 months (M3), and 12 months (M12) by Sniffin' Sticks test. Primary endpoint was defined as an absence of relapse during the observation period, with Expanded Disability Status Scale (EDSS) progression and magnetic resonance imaging (MRI) activity being the secondary endpoints. Optimal cutoff values were determined by receiver operating characteristic analyses and their predictive value assessed by multivariable Cox regression models. Results: Higher OT scores at M0, M3, and M12 were independently associated with decreased relapse probability with the strongest risk reduction at M3 (hazard ratio (HR) = 0.44, p < 0.001). Improvement of OT scores from M0 to M3 (Delta OTM3) was also associated with reduced relapse risk (HR = 0.12, p < 0.001). OT score > 6.5 at M3 was the strongest predictor of relapse freedom (HR = 0.10, p < 0.001) with high diagnostic accuracy (positive predictive value (PPV) = 87%), closely followed by Delta OTM3 > 0.5 (HR = 0.12, p < 0.001, PPV = 86%). Conclusions: OT is an independent predictor of freedom of disease activity upon DMT initiation within 5 years and may be a useful biomarker of treatment response.
引用
收藏
页码:1541 / 1552
页数:12
相关论文
共 50 条
  • [1] Olfactory threshold predicts treatment response in relapsing multiple sclerosis
    Bsteh, G.
    Hegen, H.
    Berek, K.
    Altmann, P.
    Auer, M.
    Di Pauli, F.
    Leutmezer, F.
    Rommer, P.
    Wurth, S.
    Zinganell, A.
    Deisenhammer, F.
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 53 - 53
  • [2] Olfactory threshold as a biomarker predicting treatment response in relapsing multiple sclerosis
    Bsteh, Gabriel
    Hegen, Harald
    Berek, Klaus
    Zinganell, Anne
    Wurth, Sebastian
    Auer, Michael
    Di Pauli, Franziska
    Deisenhammer, Florian
    Berger, Thomas
    NEUROLOGY, 2020, 94 (15)
  • [3] Olfactory threshold as a biomarker predicting treatment response in relapsing multiple sclerosis
    Bsteh, G.
    Hegen, H.
    Berek, K.
    Zinganell, A.
    Wurth, S.
    Auer, M.
    Di Pauli, F.
    Deisenhammer, F.
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 179 - 179
  • [4] Olfactory threshold predicts short term relapse activity in relapsing-remitting multiple sclerosis
    Bsteh, Gabriel
    Nothegger, Lisa
    Berek, Klaus
    Ladstaetter, Felix
    Raschbacher, Stefan
    Wurth, Sebastian
    Auer, Michael
    Hegen, Harald
    Di Pauli, Franziska
    Deisenhammer, Florian
    Reindl, Markus
    Lutterotti, Andreas
    Berger, Thomas
    NEUROLOGY, 2017, 88
  • [5] Olfactory threshold predicts short term relapse activity in relapsing-remitting multiple sclerosis
    Bsteh, Gabriel
    Nothegger, Lisa
    Berek, Klaus
    Ladstaetter, Felix
    Raschbacher, Stefan
    Wurth, Sebastian
    Auer, Michael
    Hegen, Harald
    Di Pauli, Franziska
    Deisenhammer, Florian
    Reindl, Markus
    Lutterotti, Andreas
    Berger, Thomas
    NEUROLOGY, 2017, 88
  • [6] Scoring treatment response in patients with relapsing multiple sclerosis
    Sormani, M. P.
    Rio, J.
    Tintore, M.
    Signori, A.
    Li, D.
    Cornelisse, P.
    Stubinski, B.
    Stromillo, M. L.
    Montalban, X.
    De Stefano, N.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (05) : 605 - 612
  • [7] DETERMINING RESPONSE TO TREATMENT WITH RITUXIMAB IN RELAPSING MULTIPLE SCLEROSIS
    Alvarez, Enrique
    Piccio, Laura
    Mikesell, Robert J.
    Trinkaus, Kim
    Tutlam, Nhial
    Ramsbottom, Michael J.
    Rapp, Neville
    Lancia, Samantha
    Parks, Becky J.
    Naismith, Robert T.
    Cross, Anne H.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (10) : 1422 - 1422
  • [8] Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis
    Bsteh, Gabriel
    Hegen, Harald
    Altmann, Patrick
    Auer, Michael
    Berek, Klaus
    Di Pauli, Franziska
    Leutmezer, Fritz
    Rommer, Paulus
    Wurth, Sebastian
    Zinganell, Anne
    Zrzavy, Tobias
    Deisenhammer, Florian
    Berger, Thomas
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (06) : 2037 - 2045
  • [9] Olfactory threshold and odour identification are markers of disease activity in relapsing-onset multiple sclerosis
    Bsteh, G.
    Lutterotti, A.
    Brendli, L.
    Vedovello, M.
    Reindl, M.
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 583 - 583
  • [10] Olfactory threshold and odour identification are markers of disease activity in relapsing-onset multiple sclerosis
    Bsteh, Gabriel
    Lutterotti, Andreas
    Berger, Thomas
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 56 - 57